Form 4: Guardant Health CCO's Equity Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported multiple equity transactions related to RSU and PBRSU vesting on January 1, 2026, including shares withheld for tax obligations.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership.
• Transactions occurred on January 1, 2026, and were made pursuant to a Rule 10b5-1 plan.
• Multiple Restricted Stock Units (RSUs) and Performance-Based Restricted Stock Units (PBRSUs) vested, leading to the acquisition of common stock.
• A total of 1,928, 15,428, 1,667, 5,688, and 2,526 shares were acquired through vesting events.
• 10,162 shares were disposed of (retained by the company) to cover tax withholding obligations at a price of $102.14 per share.
• Following these transactions, Chris Freeman beneficially owns 43,870 shares of common stock directly.
• Derivative securities beneficially owned include 5,786 Restricted Stock Units, 5,688 Performance-Based Restricted Stock Units, and 17,684 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing is a routine Form 4 indicating scheduled vesting of executive equity awards, including performance-based units, which suggests the achievement of internal company goals. The tax withholding is a standard practice. No new positive or negative operational news is presented, but the successful vesting of performance awards is a mild positive.

Positives

• Vesting of 1,928 Restricted Stock Units (granted November 7, 2022) on January 1, 2026.
• Vesting of 15,428 Performance-Based Restricted Stock Units (granted June 7, 2023) on January 1, 2026, indicating performance metric achievement.
• Vesting of 1,667 Restricted Stock Units (granted December 13, 2023) on January 1, 2026.
• Vesting of 5,688 Performance-Based Restricted Stock Units (granted February 26, 2024) on January 1, 2026, indicating performance metric achievement.
• Vesting of 2,526 Restricted Stock Units (granted November 8, 2024) on January 1, 2026.

Negatives

• 10,162 shares were disposed of at $102.14 per share to cover tax withholding obligations, reducing direct beneficial ownership.

Future Outlook

The filing indicates future vesting events for some outstanding equity awards, with the next scheduled vesting for a performance-based RSU award on January 1, 2027.

Industry Context

This Form 4 filing reflects routine executive compensation practices within the biotechnology and healthcare diagnostics industry, where equity awards like RSUs and PBRSUs are common tools for aligning executive incentives with long-term company performance and retention. The vesting of performance-based units suggests the achievement of specific corporate milestones, which is a positive indicator for the company's operational execution relative to its peers.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance-Based Restricted Stock Units (PBRSUs) for executive compensation is a standard practice across the biotechnology and healthcare sectors, similar to companies like Illumina or Exact Sciences.
• The vesting schedules, typically over three to four years with quarterly installments, are also consistent with industry norms designed to promote long-term retention and performance alignment.
• The achievement of performance metrics for PBRSUs suggests the company is meeting its internal operational goals, which is a positive sign compared to companies that might struggle to hit such targets.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and ownership changes, which can influence investor confidence.
• Employees: Reflects the company's compensation structure for executives, potentially impacting morale and retention strategies.
• Management: Demonstrates the realization of equity compensation, aligning executive interests with company performance.

Next Steps

• Remaining 75% of the November 7, 2022 RSU award vests in equal quarterly installments over the remaining three-year period after October 1, 2023.
• Remaining 67% of the December 13, 2023 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2024.
• Remaining 34% of the February 26, 2024 Performance-Based RSU award will vest on January 1, 2027.
• Remaining 67% of the November 8, 2024 RSU award vests in equal quarterly installments over the remaining two-year period after October 1, 2025.

Key Dates

Recommendation

This Form 4 filing details routine equity award vesting and tax-related share dispositions by a Chief Commercial Officer. While the vesting of performance-based units indicates the achievement of internal company goals, these are expected events and do not provide new material information to warrant a change in investment thesis. The transactions are consistent with standard executive compensation practices and do not suggest any significant operational or strategic shifts that would impact the company's valuation or future prospects. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for either upward or downward price movement.

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Equity Transactions, Restricted Stock Units, Performance-Based RSUs, Executive Compensation, Chris Freeman, Chief Commercial Officer, Stock Vesting, Rule 10b5-1